415 related articles for article (PubMed ID: 29969297)
21. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.
Zhao ZT; Ji CM; Yu WJ; Meng L; Hawro T; Wei JF; Maurer M
J Allergy Clin Immunol; 2016 Jun; 137(6):1742-1750.e4. PubMed ID: 27040372
[TBL] [Abstract][Full Text] [Related]
22. Long-term effects of omalizumab on peripheral blood cells and C-reactive protein levels in patients with chronic spontaneous urticaria.
Akdogan N; Demirel Ogut N; Dogan S; Atakan N
Dermatol Ther; 2019 Jul; 32(4):e12966. PubMed ID: 31087491
[TBL] [Abstract][Full Text] [Related]
23. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
Cakmak ME; Yeğit OO; Öztop N
Int Arch Allergy Immunol; 2023; 184(3):236-242. PubMed ID: 36543155
[TBL] [Abstract][Full Text] [Related]
25. Factors related to omalizumab resistance in chronic spontaneous urticaria.
Magen E; Chikovani T; Waitman DA; Kahan NR
Allergy Asthma Proc; 2019 Jul; 40(4):273-278. PubMed ID: 31262381
[No Abstract] [Full Text] [Related]
26. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria.
Kolkhir P; Altrichter S; Hawro T; Maurer M
Allergy; 2018 Apr; 73(4):940-948. PubMed ID: 29130488
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
28. Does omalizumab modify a course of recalcitrant chronic spontaneous urticaria?: A retrospective study in Asian patients.
Kulthanan K; Tuchinda P; Likitwattananurak C; Weerasubpong P; Chularojanamontri L
J Dermatol; 2018 Jan; 45(1):17-23. PubMed ID: 29044681
[TBL] [Abstract][Full Text] [Related]
29. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.
Hoşgören-Tekin S; Eyüboğlu İP; Akkiprik M; Giménez-Arnau AM; Salman A
Arch Dermatol Res; 2024 May; 316(6):261. PubMed ID: 38795119
[TBL] [Abstract][Full Text] [Related]
31. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
[TBL] [Abstract][Full Text] [Related]
32. Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.
Eghrari-Sabet J; Sher E; Kavati A; Pilon D; Zhdanava M; Balp MM; Lefebvre P; Ortiz B; Bernstein JA
Allergy Asthma Proc; 2018 May; 39(3):191-200. PubMed ID: 29458456
[TBL] [Abstract][Full Text] [Related]
33. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
34. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.
Kulthanan K; Tuchinda P; Chularojanamontri L; Likitwattananurak C; Ungaksornpairote C
J Dermatolog Treat; 2017 Mar; 28(2):160-165. PubMed ID: 27388043
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study.
Cakmak ME
Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494
[TBL] [Abstract][Full Text] [Related]
36. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
38. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
39. D-dimer levels decline after immunosuppressive treatment rather than anticoagulant treatment in severe autoimmune chronic spontaneous urticaria.
Baskurt D; Sarac E; Asero R; Kocatürk E
Eur Ann Allergy Clin Immunol; 2024 Jan; 56(1):42-44. PubMed ID: 36305339
[TBL] [Abstract][Full Text] [Related]
40. Omalizumab may not inhibit mast cell and basophil activation in vitro.
Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]